Neurodegeneration – Webinars and Online Events

Recent technological progress has allowed biologists to measure an unprecedented number of these molecules throughout an organism, providing unique insights into the physiological and pathological conditions of cells and organs, including the aging

MALDI mass spectrometry imaging has emerged as a powerful technology platform for spatially resolved analysis and visualization of a wide range of molecules – including drugs, metabolites, peptides and more – in pharmaceutical R&D, clinical research and basic science. Advances in MALDI workflows are making the technique more accessible.
In this webinar, our speaker will discuss how a new MALDI workflow can be used to analyze lipids in degenerative disease and Alzheimer’s models, contextualizing lipid distribution by enabling comparison to multiple protein markers.
He’ll also highlight how the new workflow can be applied to the study of tumor subtypes and the tumor microenvironment.

In this webinar, we’ll explore how integrating proteomics with systems biology sheds light on the complexities of AD pathology.

This webinar explores a highly sensitive, automated assay workflow to provide high-quality results for low-abundance biomarkers in serum, plasma and cerebrospinal fluid.

Explore the tools and techniques being used to study diseases in the lab. Discover how advances in cell culture and disease modeling are supporting diagnostic and therapeutic development.

Alzheimer’s disease (AD) is the most common form of dementia in the elderly population. While several peptide and protein biomarkers in cerebrospinal fluid (CSF) have been used for AD diagnosis, an unequivocal diagnosis in the early phases of AD is still lacking.

In this webinar, our speaker will discuss the role of glucosyl and galactosyl ceramides as biomarkers and how their misregulation can be an identifier for various disease states including, but not limited to, Parkinson’s, Krabbe and Gaucher diseases.

Dr. Walker will discuss how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.

This popular online event will once again bring together leading scientists in the field as they highlight the latest advancements in translational proteomics and metabolomics. Presentations will cover areas ranging from uncovering the molecular mechanisms of disease pathology, to the latest technological developments in diagnostics and treatment.

bit.bio’s first-of-its-kind precision cellular reprogramming technology, opti-ox™, addresses the limitations of lot consistency, cell definition and scalability by controlling the precise expression of cell-fate determining genetic factors.